Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
TNFRSF10C antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB |
|---|---|
| Primary Accession | O14798 |
| Other Accession | NM_003841, NP_003832 |
| Reactivity | Human |
| Predicted | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 25kDa |
| Gene ID | 8794 |
|---|---|
| Alias Symbol | CD263, DCR1, LIT, MGC149501, MGC149502, TRAILR3, TRID, TRAIL-R3, DCR1-TNFR |
| Other Names | Tumor necrosis factor receptor superfamily member 10C, Antagonist decoy receptor for TRAIL/Apo-2L, Decoy TRAIL receptor without death domain, Decoy receptor 1, DcR1, Lymphocyte inhibitor of TRAIL, TNF-related apoptosis-inducing ligand receptor 3, TRAIL receptor 3, TRAIL-R3, TRAIL receptor without an intracellular domain, CD263, TNFRSF10C, DCR1, LIT, TRAILR3, TRID |
| Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
| Reconstitution & Storage | Add 50 ul of distilled water. Final anti-TNFRSF10C antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
| Precautions | TNFRSF10C antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | TNFRSF10C |
|---|---|
| Synonyms | DCR1, LIT, TRAILR3, TRID |
| Function | Receptor for the cytotoxic ligand TRAIL. Lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. May protect cells against TRAIL mediated apoptosis by competing with TRAIL- R1 and R2 for binding to the ligand. |
| Cellular Location | Cell membrane; Lipid-anchor, GPI-anchor. |
| Tissue Location | Higher expression in normal tissues than in tumor cell lines. Highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Receptor for the cytotoxic ligand TRAIL. Lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. May protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.
References
MacFarlane M.,et al.J. Biol. Chem. 272:25417-25420(1997).
Degli-Esposti M.A.,et al.J. Exp. Med. 186:1165-1170(1997).
Pan G.,et al.Science 277:815-818(1997).
Sheridan J.P.,et al.Science 277:818-821(1997).
Schneider P.,et al.FEBS Lett. 416:329-334(1997).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
